Tarsus Pharmaceuticals, Inc. (TARS)

Market Cap	1.99B
Revenue (ttm)	182.95M
Net Income (ttm)	-115.55M
Shares Out	38.38M
EPS (ttm)	-3.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	499,088
Open	50.58
Previous Close	50.65
Day's Range	49.56 - 52.30
52-Week Range	20.08 - 57.28
Beta	1.06
Analysts	Strong Buy
Price Target	63.67 (+23.06%)
Earnings Date	May 7, 2025

About TARS

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company devel...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 323
• Stock Exchange: NASDAQ
• Ticker Symbol: TARS
• Website: https://www.tarsusrx.com

Financial Performance

In 2024, Tarsus Pharmaceuticals's revenue was $182.95 million, an increase of 948.62% compared to the previous year's $17.45 million. Losses were -$115.55 million, -14.97% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price forecast is $63.67, which is an increase of 23.06% from the latest price.

Price Target

$63.67

(23.06% upside)

Analyst Consensus: Strong Buy